Edition:
United States

NantHealth Inc (NH.OQ)

NH.OQ on NASDAQ Stock Exchange Global Select Market

2.41USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$2.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,215
52-wk High
$5.25
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Nanthealth Inc QTRLY Loss Per Share From Continuing Operations $0.20
Thursday, 9 Aug 2018 04:15pm EDT 

NantHealth Inc ::NANTHEALTH REPORTS 2018 SECOND-QUARTER FINANCIAL RESULTS.Q2 REVENUE $22 MILLION.QTRLY LOSS PER SHARE FROM CONTINUING OPERATIONS $0.20.QTRLY TOTAL NET LOSS PER SHARE BASIC AND DILUTED $0.21.QTRLY TOTAL NET REVENUE $22 MILLION VERSUS $23.5 MILLION.  Full Article

Nanthealth Reports Q4 Loss Per Share $0.20
Wednesday, 14 Mar 2018 04:15pm EDT 

March 14 (Reuters) - Nanthealth Inc ::NANTHEALTH REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR FINANCIAL RESULTS.Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.07 FROM CONTINUING OPERATIONS.Q4 LOSS PER SHARE $0.20.Q4 REVENUE $22.3 MILLION VERSUS I/B/E/S VIEW $23.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

NantHealth reports 2017 third quarter financial results
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Nanthealth Inc :NantHealth reports 2017 third quarter financial results; GPS revenue doubles from preceding quarter.Q3 adjusted non-GAAP loss per share $0.13 from continuing operations.Q3 loss per share $0.20 from continuing operations.Q3 loss per share $0.37.Q3 revenue $21.8 million versus $20.7 million.Q3 revenue view $29.2 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.NantHealth Inc - ‍ restructuring plan was initiated in Q3, plan expected to generate annualized cost savings of more than $70 million​.  Full Article

NantHealth reports Q2 loss per share $0.58
Thursday, 10 Aug 2017 04:15pm EDT 

Aug 10 (Reuters) - NantHealth Inc -:NantHealth reports 2017 second quarter financial results; implements plan to focus on core competencies, enhance profitability and position for growth of artificial intelligence for cancer care.Q2 adjusted non-gaap loss per share $0.18.Q2 loss per share $0.58.Q2 revenue $26.2 million versus i/b/e/s view $31.3 million.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Nanthealth says GPS cancer is now covered by Sistemas Medicos Nacionales
Monday, 7 Aug 2017 10:29am EDT 

Aug 7 (Reuters) - Nanthealth Inc :GPS cancer is now covered by Sistemas Medicos Nacionales.  Full Article

Nanthealth Inc - ‍Blue Cross and Blue Shield of Nebraska has signed a three-year contract extension for NaviNet Open​
Tuesday, 1 Aug 2017 08:00am EDT 

Aug 1 (Reuters) - Nanthealth Inc :Nanthealth Inc - ‍Blue Cross and Blue Shield of Nebraska has signed a three-year contract extension for NaviNet Open​.  Full Article

Nanthealth Q1 adjusted non-gaap loss per share $0.24
Wednesday, 10 May 2017 04:15pm EDT 

May 10 (Reuters) - Nanthealth Inc ::Nanthealth reports 16% increase in 2017 first quarter total net revenue; saas revenue rose 11% and gps adoption continues to climb.Q1 adjusted non-gaap loss per share $0.24.Q1 loss per share $0.34.Q1 revenue rose 16 percent to $22.5 million.Q1 revenue view $29.1 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Nanthealth posts Q4 adj. loss per share $0.18
Thursday, 30 Mar 2017 04:23pm EDT 

Nanthealth Inc : Nanthealth reports 72 pct increase in full year 2016 total net revenue to $100 million with saas revenue increasing more than 181 pct and increasing GPS cancer adoption . Q4 adjusted non-GAAP loss per share $0.18 . Q4 loss per share $0.49 . Q4 revenue $24.1 million versus I/B/E/S view $27.9 million .Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

NantHealth announces pricing of $100 mln of 5.50 pct convertible notes
Friday, 16 Dec 2016 08:00am EST 

NantHealth Inc - : Pricing of an aggregate of $100 million principal amount of 5.50% convertible senior notes due 2021 . Estimates that aggregate net proceeds from offerings will be approximately $96.2 million .NantHealth Inc announces pricing of $100 million of 5.50 pct convertible notes.  Full Article

NantHealth, NantKwest and NantOmics announce availability of GPS cancer and phase i - iii quilt trials through the U.S. National Institutes of Health's ClinicalTrials.gov
Thursday, 8 Dec 2016 08:00am EST 

NantHealth Inc :NantHealth, NantKwest and NantOmics announce availability of GPS cancer and phase i - iii quilt trials through the U.S. National Institutes of Health's ClinicalTrials.gov.  Full Article

BRIEF-NantHealth Reports Q1 Revenue $22.3 Mln

* Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.12 FROM CONTINUING OPERATIONS